2011
Breast Medical Oncologists' Use of Standard Prognostic Factors to Predict a 21‐Gene Recurrence Score
Kamal AH, Loprinzi CL, Reynolds C, Dueck AC, Geiger XJ, Ingle JN, Carlson RW, Hobday TJ, Winer EP, Goetz MP. Breast Medical Oncologists' Use of Standard Prognostic Factors to Predict a 21‐Gene Recurrence Score. The Oncologist 2011, 16: 1359-1366. PMID: 21934103, PMCID: PMC3228065, DOI: 10.1634/theoncologist.2011-0048.Peer-Reviewed Original ResearchConceptsRecurrence scorePrognostic criteriaRS riskTreatment recommendationsIntermediate-risk casesHormone receptor statusLymph node negativeProspective clinical trialsStandard prognostic factorsIntermediate recurrence scoreAbility of oncologistsChemotherapy useChemotherapy recommendationsChemotherapy benefitNode negativePrognostic factorsReceptor statusHistologic typeAcademic oncologistsOncologists' useTumor gradeClinical trialsBreast cancerRS categoryOncologist's ability
2007
How well do standard prognostic criteria predict oncotype DX (ODX) scores?
Kamal A, Loprinzi C, Reynolds C, Dueck A, Geiger X, Ingle J, Carlson R, Hobday T, Winer E, Perez E, Goetz M. How well do standard prognostic criteria predict oncotype DX (ODX) scores? Journal Of Clinical Oncology 2007, 25: 576-576. DOI: 10.1200/jco.2007.25.18_suppl.576.Peer-Reviewed Original ResearchODX scoresPrognostic criteriaBreast cancerExpert breast pathologistsMayo Clinic patientsOncotype DX scoreAssessment of ERAdjuvant chemotherapyIntermediate riskBreast pathologistsClinic patientsTumor sizeAcademic oncologistsTumor gradeHigh riskTumor slidesStandardized criteriaClinical casesPatientsOncologistsGene expression profilingSignificant financial relationshipChemotherapyODXScores